Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

CompletedOBSERVATIONAL
Enrollment

185

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

April 29, 2025

Study Completion Date

April 29, 2025

Conditions
Metastatic Breast Cancer
Trial Locations (12)

11745

Dar El Salam Oncology Hospital, Cairo

11796

National Cancer Institute, Cairo

11941

King Hussein Cancer Center, Amman

Unknown

Alexandria School of Medicine/Clinical Research Center CRC, Alexandria

Ain Shams University Hospital, Cairo

American University of Beirut Medical Center, Beirut

Hôtel Dieu de France (HDF), Beirut

Saint Joseph Hospital - Cancer Centers of Colorado, Jdeidé - Metn

Hammoud Hospital University Medical Center (HHUMC), Sidon

Hamad Medical Corporation, Doha

King Fahad Specialist Hospital KFSH-Dammam, Dammam

National Guard Hospital, Riyadh, Riyadh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04937660 - Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC | Biotech Hunter | Biotech Hunter